News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioCryst Pharmaceuticals, Inc.
NEWS
JOBS
IN THE PRESS
NEWS
BioCapital
Ebola Clinical Trials: Big Name Players In The Ebola Race
October 20, 2014
·
12 min read
Biotech Beach
The Day In Review: Novartis Pharmaceuticals Corporation Gets Approval For Hypertensive Drug Tekturna
March 6, 2007
·
1 min read
Biotech Beach
The Week In Review: Biotech Ends Q3 With A Bang
October 3, 2006
·
1 min read
Biotech Beach
The Day In Review: Amgen Buys Avidia, Inc. For $290 Million
October 3, 2006
·
1 min read
Biotech Bay
The Day In Review: Amgen Gets Approval For Vectibix
September 27, 2006
·
1 min read
Biotech Beach
The Day In Review: Immunicon Corporation Rises On AstraZeneca PLC Deal
August 7, 2006
·
1 min read
Biotech Beach
The Day In Review: Pfizer Inc. Buys Obesity Compound From Bayer Corporation
June 14, 2006
·
1 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Drug Development
ORLADEYO® (berotralstat) Approved in Peru
July 10, 2024
·
5 min read
Bio NC
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2024
June 4, 2024
·
1 min read
Bio NC
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
June 2, 2024
·
8 min read
Bio NC
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
May 14, 2024
·
5 min read
Policy
ORLADEYO® (berotralstat) Approved in Mexico
May 13, 2024
·
5 min read
Bio NC
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)
May 9, 2024
·
7 min read
Bio NC
BioCryst to Present at Upcoming May 2024 Investor Conferences
May 7, 2024
·
1 min read
Business
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
May 6, 2024
·
14 min read
Bio NC
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2024
May 3, 2024
·
1 min read
Business
BioCryst to Report First Quarter 2024 Financial Results on May 6
April 22, 2024
·
1 min read
